Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Frequently asked questions
What sector does Alar Pharmaceuticals Inc. (6785) operate in?
Alar Pharmaceuticals Inc. belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Alar Pharmaceuticals Inc. (6785) current stock price?
As of the latest data, Alar Pharmaceuticals Inc. stock price is NT$99.60, with a previous close of NT$100.00. Alar Pharmaceuticals Inc. lost -NT$0.40 in the last trading session, representing a -0.4% loss.
What is Alar Pharmaceuticals Inc. (6785) current market capitalization?
Alar Pharmaceuticals Inc. market cap is approximately 6.65 billion.
What is Alar Pharmaceuticals Inc. (6785) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.69, and the forward EPS is NT$0.37.
Does Alar Pharmaceuticals Inc. (6785) pay dividends?
No. Alar Pharmaceuticals Inc. does not pay a dividend.
What is Alar Pharmaceuticals Inc. (6785) beta (volatility) score?
Alar Pharmaceuticals Inc. has a beta of 0.124, indicating lower volatility than the overall market.